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Background: Influenza virus infections are responsible for significant morbidity and mortality in both pediatric and
adult populations worldwide. Rapid and accurate diagnosis of influenza is necessary for appropriate patient
management during the influenza season and for optimal utilization of anti-influenza therapy. We prospectively
tested the accuracy of a simple and rapid diagnostic method.
Methods: Ninety-eight samples (nasal and pharyngeal swabs) from patients with upper respiratory tract infection
symptoms who presented to primary healthcare centres in Barcelona (Spain) were prospectively analyzed. The samples
were collected as part of influenza surveillance program. Samples that had enough volume to make the new test after
aliquoting the amount needed to perform routine tests were included. None of the samples were pre-selected as a
result of their status in relation to influenza virus. Samples were analyzed by in-house real-time PCR and Alere™ i
Influenza A & B (Alere™ i), which uses isothermal amplification of nucleic acids for the qualitative detection of influenza
A and B in nasal swabs transported in viral transport media. The two techniques were compared by positive percent
agreement (PPA) and negative percent agreement (NPA). Statistical analysis was performed with Stata.
Results: Of the 98 samples analysed 90 were concordant; 46 (46.9%) were positive and 44 (44.9%) were negative. Five
samples showed invalid results with the Alere™ i test and could be not re-tested due to insufficient sample volume
and were not included in the final statistical analysis. In the 93 remaining samples, the Alere™ i test showed 97% of
accuracy having correctly classified 90 samples. We obtained discordant results in 3 samples (3%). The PPA was 93.8%
for influenza A and 94.1% for influenza B, and NPA was 100% for influenza A and influenza B virus. In addition, the
Alere™ i was very rapid (15 minutes or less) and extremely easy to use.
Conclusions: The Alere™ i test provided a good correlation compared to the real-time PCR test for the diagnosis of
influenza. Since this method can be performed in minutes, it allows immediate, accurate clinical decisions to prescribe
appropriate antiviral treatment or isolation of patients.
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Influenza virus infections are responsible for significant
morbidity and mortality in both pediatric and adult
populations worldwide. Rapid and accurate diagnosis of
influenza is necessary for appropriate patient manage-
ment during influenza season and for optimal utilization
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unless otherwise stated.Molecular testing, such as real-time PCR, is more sen-
sitive, specific and less time consuming than viral culture
and immunofluorescence assays. However, real-time PCR
is technically demanding and quite laborious and must be
done in a sophisticated laboratory. Rapid antigen-based
assays are simple and fast methods that have been widely
used for the detection of influenza virus but with its
major limitation is their low and widely variable sensi-
tivity (10%–80%) [3-8].
Alere™ i (Scarborough, Maine, USA) is a rapid molecu-
lar diagnostic test using nicking endonuclease amplifica-
tion reaction, a kind of isothermal amplification, and itl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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enza virus type A and B from nasal swab specimens in
viral transport medium. Alere™ i enables nucleic acid
amplification without the need for the long thermal cy-
clers, allowing result to be obtained in 15 minutes or
less. It does not require a DNA purification step which
is time-consuming, more complex and costly. For these
reasons, it can be performed anywhere, without the need
for sophisticated laboratories.
The aim of this study was to compare Alere™ i Influ-
enza A & B with an in-house real-time PCR for influ-
enza virus detection in prospectively recruited patients
presenting with flu symptoms during the 2011–2012 in-
fluenza season in Barcelona, Spain.
Methods
Data and sample collection
From January 7th to April 30th, 2012, excess samples (nasal
and pharyngeal swabs) from patients presenting flu-like
symptoms at primary care health centers were prospectively
analyzed as part of the “Influenza Surveillance in Catalonia,
Spain” program available at the Health Department of
Generalitat de Catalunya website (http://grip.gencat.cat/ca/
la_grip_professionals/documentacio/). This study was
approved by the Ethic Committee of Hospital Clinic of
Barcelona and patients gave informed consent.
Specimens were collected using swabs and inserted into
sample collection tube (kit of 3 ml UTM™ medium with 2
polyester swabs, Copan Diagnostics Inc., Murrieta, CA,
USA) and were shipped the same day of collection at a
temperature of 2°C to −4°C. Samples that had enough vol-
ume to make the new test after aliquoting the amount
needed to perform routine tests were included. None of
the samples were pre-selected as a result of their status in
relation to influenza virus, and were sequentially included
in the study.
Processing sample
Samples were processed in the laboratory in Biosafety
Level 2 Plus facilities, distributed in several aliquots and
were processed simultaneously with routine testing within
24 hours of receipt at the laboratory. Samples came week-
ends were processed within three days. An aliquot with
200 μL of each sample was used to perform the Alere™ i
test according to the manufacturer's instructions (Figure 1).
Simultaneously, a 300 μL aliquot was taken for total nu-
cleic acids extraction and eluted in 25 μL of RNase-free
elution buffer using the automatic QIAsymphony system
(Qiagen, Hilden, Germany) according to the manufactur-
er's instructions. Subsequently, two specific 1-step multi-
plex real-time PCR was carried out using the Stratagene
Mx3000P QPCR Systems (Agilent Technologies, Santa
Clara, CA, USA), described elsewhere [9], were used for
typing A/B influenza virus (sensitivity was 10 and 103copies/μL, respectively) and subtyping influenza A virus
(sensitivity was 102, 103 and 10 copies/μL for H1, H3 and
H5 RNA, respectively) [9].
Statistical analysis
The Alere™ i test and real-time PCR diagnostic tech-
niques were compared by PPA and NPA, considering
the real-time PCR test as an imperfect reference stand-
ard. Estimates were reported along their 95% confidence
intervals (95% CI) [10-12]. Statistical analysis was per-
formed with Stata (StataCorp. 2013. Stata: Release 13.
Statistical Software. College Station, TX: StataCorp LP).
Results and discussion
Ninety-eight samples were collected from 40 (41%) female
and 58 (59%) male patients of whom 46 (47%) were youn-
ger than 18 years old. Five samples showed invalid results
with the Alere™ i test, of which 3 were positive and 2 nega-
tive by PCR. These samples could not be re-tested due to
insufficient sample volume and were not included in the
final statistical analysis. In the 93 remaining samples, the
Alere™ i test showed 97% of accuracy having correctly
classified 90 samples; 46 as true positive and 44 as true
negative. Among the true positive samples, 30 were identi-
fied as influenza A virus and 16 as B virus. The Alere™ i
test did not detect virus in any specimens that were not
confirmed as positive by the PCR assay. All influenza A
virus identified were subtyped by multiplex real-time PCR
as influenza A H3. Discrepancies were noted in only 3
samples (2 influenza A virus and 1 influenza B virus), all
classified as false negative by Alere™ i. The mean real-time
PCR threshold cycle (Ct) values of all 46 positives were 21
while the mean Ct value of the samples with discordant
or invalid results was 20.3 and 25, respectively. The PPA
of the Alere™ i test was 93.8% for influenza A and 94.1%
for influenza B, respectively. The NPA was 100% for
both influenza A and influenza B virus (Table 1). The
average working time for the Alere™ i test was less than
15 minutes while that for real-time PCR assay was lon-
ger than 4 hours.
In the last years, rapid antigen-based assays have been
utilized for the detection of influenza virus [13]. Generally,
positive results of these rapid methods correlate well with
influenza virus infection; however, the major limitation is
the low and widely variable sensitivity [14-16]. An ideal
rapid influenza diagnostic test should have a diagnostic ac-
curacy approaching or equivalent to the most sensitive
methods, such as viral culture or real-time PCR.
In this study, we compared the Alere™ i test with an in-
house real-time PCR for the detection of influenza virus.
The accuracy of the Alere™ i test was 97% and the overall
PPA and NPA were very good with the additional advan-
tage of rapid and easy use. Recently, Bell et al. [17] have
also reported good performance on comparing Alere™ i
Figure 1 Steps for run a test with Alere™ i Influenza A&B. RCVR: Sample receivers. CARTRDG: Transfer Cartridges.
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was 93%).
In our study, the mean Ct was 21 (the range was 16–29),
it may have been low due to sample collection at the onset
of symptoms. Additionally participants were recruited at
the time of maximum virus circulation. All patients had a
clinical diagnosis of upper respiratory tract infection, which
is associated with low Ct. We also included patients lessTable 1 Alere™ i and real-time PCR
Organism N° detected: Alere/RT-PCR
+/+(a) +/−(b) −/+(c ) −/−(d)
Influenza virus A 30 0 2 44
Influenza virus B 16 0 1 44
Alere™: the Alere™ i Influenza A&B.
PCR: in-house real-time PCR.
PPA: positive percent agreement.
NPA: negative percent agreement.than 18 years, who generally have more viruses in their
upper respiratory secretions. The samples studied were
collected prospectively during flu season 2011–2012; we
believe it is necessary to conduct additional studies to
assess the performance of the test against other sub-
types of influenza virus.
Our study has some limitations: the percentage of invalid
results was proportionally greater than that described byPPA NPA
a/(a + c) (%) 95% CI d/(b + d) (%) 95% CI
93,8 79.2 – 99.2 100 92.0 – 100.0
94,1 71.3 – 99.9 100 92.0 – 100.0
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size and some handling errors at the beginning of test use.
Other limitation was the impossibility to retest samples
with invalid results according to the Package Insert due to
the lack of samples. It was of note that the H1N1 subtype
was not observed in our study population. Indeed, the
H3N2 subtype of influenza virus was found in all the sam-
ples, but we did not detect H1N1 or any other subtype,
therefore we cannot extend our observations to all isolates.
Nevertheless, we think that the test should detect other
subtypes including H1N1 such as the data obtained by Nie
et al. [18] who found no significant difference on compar-
ing Alere™ i with a PCR technique.
Conclusions
Alere™ i combines the speed of a rapid antigen with the
sensitivity of PCR in the diagnosis of influenza. In
addition, it may be used at any time and any day and
without specialized personnel. These characteristics
make this test particularly valuable for primary care phy-
sicians during the influenza epidemic season for point-
of-care testing because it allows immediate and accurate
clinical decisions to prescribe appropriate antiviral treat-
ment or the isolation of these patients.
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